Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 1 (1)

Trial Status

Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT06914479Phase 1Recruiting

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

NCT03823144Not ApplicableRecruiting

Intravital Microscopy in Human Solid Tumors

Showing all 2 trials

Research Network

Activity Timeline